Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Stuttgart - Delayed Quote • EUR AB Science (A8D.SG) Follow Compare 1.3580 +0.0100 +(0.74%) At close: April 17 at 11:10:27 AM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for A8D.SG 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: A8D.SG View More All News Press Releases SEC Filings AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch AB Science today provides an update on its masitinib platform AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET AB Science will participate in the Biomed Forum investors conference AB Science provides a summary of the webcast held on December 16, 2024 AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS AB Science: Revenues for the first half of 2024 and update on AB Science’s activities AB Science announces a slight delay in the publication of its 2024 half-year financial report